Clinical trials: Steroid Refractory
Asthma
Immune Interactions in Severe Asthma
This research study is being done to learn more about severe asthma by comparing people with severe asthma to those with milder forms of asthma and people without asthma, at baseline and over time.
- Trial name
- NCT02566668
- Testing
- 1 year Observational Follow-up
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Chronic Graft vs Host Disease
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
- Trial name
- GVHD-TReG (NCT03683498)
- Testing
- Regulatory T-cell enriched infusion
- Where
- Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease
Identification of Novel Targetable Kinases in SR-a GvHD
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Trial name
- NCT04342442
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Graft vs Host Disease
A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease
Phase 1/2 clinical study for the treatment of steroid-refractory chronic graft versus host disease after an allogeneic transplant of hematopoietic progenitors with donor CliniMACS-selected regulatory T cells
- Trial name
- TREGeneration (NCT02385019)
- Testing
- Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
- Where
- 3 sites in Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes
Uveitis, Posterior, Uveitis, Anterior
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed…
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT06085079
- Testing
- Ixekizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye Research and Surgery Institution
Graft vs Host Disease
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease
Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties. Following a bone marrow/peripheral blood stem cell transplant, a proportion of patients develop a condition called 'graft versus host disease'…
- Trial name
- NCT00314483
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- India
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen